|Solubility:||DMSO 100 mg/mL|
|Long-term Storage:||at -20℃|
|HPLC:||Shows Min >99% purity|
|H-NMR:||Consistent with structure|
|Description:||MGCD265 is a novel multitargeted receptor tyrosine kinase (RTK) inhibitor that targets the mesenchymal epithelial transition (c-Met) and the vascular endothelial growth factor (VEGF) receptors (VEGFR1, VEGFR2, and VEGFR3).|
|Stability and Solubility Advice:|| Information concerning product stability, particularly in solution, has rarely been reported and in most cases we can only offer a general guide.
We recommend that stock solutions, once prepared, are stored aliquoted in tightly sealed vials at -20°C or below and used within 1 month.